North America Pharmacokinetics and Pharmacodynamics Market Research Report Forecast to 2032
Market Overview
North America Pharmacokinetics and Pharmacodynamics Market is anticipated to register a significant CAGR of 7.09% by 2032. Pharmacokinetics (PK) and pharmacodynamics (PD) are two closely related branches of pharmacology that deal with the study of drugs and their effects on the body. Pharmacokinetics (PK) is the study of how the body handles a drug, from the time it is administered until it is eliminated. It encompasses the processes of absorption, distribution, metabolism, and excretion (ADME). Furthermore, pharmacodynamics (PD) is the study of the effects of drugs on the body. It investigates how drugs interact with molecular targets, such as receptors or enzymes, to produce their physiological effects. PD studies aim to characterize the relationship between drug concentration and its effect, including the onset, duration, and intensity of the effect.
The North America pharmacokinetics and pharmacodynamics market is predicted to expand due to the increasing prevalence of chronic diseases, advancements in technology and analytical techniques, and strong healthcare infrastructure. Additionally, the shortage of skilled and experienced professionals will provide growth opportunities for the market in the future. However, the growing popularity of personalized medicine might hamper the market's growth in the forecast period.
Market Segmentation
Based on service type, the North America pharmacokinetics and pharmacodynamics market has been segmented into pharmacokinetic services, pharmacodynamic services. pharmacokinetic services further segmented into drug absorption studies, drug distribution studies, drug metabolism studies, drug excretion studies, and others. pharmacodynamic services further segmented into receptor binding studies, biomarker analysis, and others.
Based on drug type, the North America pharmacokinetics and pharmacodynamics market has been segmented into small molecules and large molecules.
Based on application, the North America pharmacokinetics and pharmacodynamics market has been segmented into oncology, cardiovascular, infectious disease, neurology, immunology, and others.
Based on end user, the North America pharmacokinetics and pharmacodynamics market has been segmented into pharmaceutical and biotechnology companies, academic and research institutions, and others.
The North America pharmacokinetics and pharmacodynamics market is segmented into the US and Canada. The US held the largest market share of 82.34% based on region and Canada is anticipated to dominate the overall pharmacokinetics and pharmacodynamics market during the forecast period.
Major Players
The key players operating in the market are LGC Limited Eurofins Scientific, Charles River Laboratories, Evotec AG, SGS Société Générale de Surveillance SA, LGC Limited, Eurofins Scientific, Charles River Laboratories, Evotec AG, and SGS Société Générale de Surveillance SA.
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 29
TABLE 2 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 44
TABLE 3 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY COUNTRY, 2019–2032 (USD MILLION) 45
TABLE 4 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE,
2019–2032 (USD MILLION) 46
TABLE 5 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG ABSORPTION STUDIES, BY COUNTRY,
2019–2032 (USD MILLION) 46
TABLE 6 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG DISTRIBUTION STUDIES, BY COUNTRY, 2019–2032 (USD MILLION) 46
TABLE 7 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG METABOLISM STUDIES, BY COUNTRY,
2019–2032 (USD MILLION) 47
TABLE 8 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG EXCRETION STUDIES, BY COUNTRY,
2019–2032 (USD MILLION) 47
TABLE 9 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY,
2019–2032 (USD MILLION) 47
TABLE 10 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES,
BY COUNTRY, 2019–2032 (USD MILLION) 48
TABLE 11 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES,
BY TYPE, 2019–2032 (USD MILLION) 48
TABLE 12 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR RECEPTOR BINDING STUDIES, BY COUNTRY,
2019–2032 (USD MILLION) 48
TABLE 13 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR BIOMARKER ANALYSIS, BY COUNTRY,
2019–2032 (USD MILLION) 49
TABLE 14 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY,
2019–2032 (USD MILLION) 49
TABLE 15 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY DRUG TYPE, 2019–2032 (USD MILLION) 51
TABLE 16 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR SMALL MOLECULES, BY COUNTRY,
2019–2032 (USD MILLION) 52
TABLE 17 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR LARGE MOLECULES, BY COUNTRY,
2019–2032 (USD MILLION) 52
TABLE 18 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY THERAPEUTIC AREA,
2019–2032 (USD MILLION) 54
TABLE 19 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR ONCOLOGY, BY COUNTRY,
2019–2032 (USD MILLION) 55
TABLE 20 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR CARDIOVASCULAR, BY COUNTRY,
2019–2032 (USD MILLION) 55
TABLE 21 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR INFECTIOUS DISEASES, BY COUNTRY,
2019–2032 (USD MILLION) 56
TABLE 22 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR NEUROLOGY, BY COUNTRY,
2019–2032 (USD MILLION) 56
TABLE 23 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR IMMUNOLOGY, BY COUNTRY,
2019–2032 (USD MILLION) 56
TABLE 24 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY,
2019–2032 (USD MILLION) 57
TABLE 25 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY END USER, 2019–2032 (USD MILLION) 59
TABLE 26 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2032 (USD MILLION) 60
TABLE 27 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR ACADEMIC AND RESEARCH
INSTITUTIONS, BY COUNTRY, 2019–2032 (USD MILLION) 60
TABLE 28 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY,
2019–2032 (USD MILLION) 61
TABLE 29 NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY COUNTRY, 2019–2032 (USD MILLION) 63
TABLE 30 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 64
TABLE 31 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE,
2019–2032 (USD MILLION) 65
TABLE 32 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY TYPE,
2019–2032 (USD MILLION) 65
TABLE 33 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY DRUG TYPE, 2019–2032 (USD MILLION) 65
TABLE 34 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY THERAPEUTIC AREA, 2019–2032 (USD MILLION) 66
TABLE 35 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY END USER, 2019–2032 (USD MILLION) 66
TABLE 36 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019–2032 (USD MILLION) 66
TABLE 37 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE,
2019–2032 (USD MILLION) 67
TABLE 38 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY TYPE,
2019–2032 (USD MILLION) 67
TABLE 39 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY DRUG TYPE, 2019–2032 (USD MILLION) 67
TABLE 40 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY THERAPEUTIC AREA, 2019–2032 (USD MILLION) 68
TABLE 41 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY END USER, 2019–2032 (USD MILLION) 68
TABLE 42 PUBLIC PLAYERS STOCK SUMMARY 72
TABLE 43 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 72
TABLE 44 CREATIVE BIOARRAY: PRODCUTS OFFERED 74
TABLE 45 QUANTICATE: SERVICES OFFERED 77
TABLE 46 PACIFIC BIOLABS, INC.: SERVICES OFFERED 79
TABLE 47 ALLUCENT: SERVICES OFFERED 82
TABLE 48 CHARLES RIVER LABORATORIES: SERVICES OFFERED 86
TABLE 49 EVOTEC AG: SERVICES OFFERED 89
TABLE 50 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: SERVICE OFFERED 93
TABLE 51 LGC LIMITED: SERVICES OFFERED 95
TABLE 52 EUROFINS SCIENTIFIC: SERVICES OFFERED 98
TABLE 53 CREATIVE BIOLABS: SERVICES OFFERED 101
LIST OF FIGURES
FIGURE 1 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET: STRUCTURE 16
FIGURE 2 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET: MARKET GROWTH FACTOR
ANALYSIS (2022-2032) 32
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032) 34
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032) 35
FIGURE 5 VALUE CHAIN ANALYSIS OF THE NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET 37
FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET 39
FIGURE 7 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, SERVICE TYPE SEGMENT ATTRACTIVENESS,
2019-2032 (USD MILLION) 43
FIGURE 8 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2022 & 2032 (USD MILLION) 44
FIGURE 9 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY SERVICE TYPE, 2022 45
FIGURE 10 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, DRUG TYPE SEGMENT ATTRACTIVENESS,
2019-2032 (USD MILLION) 50
FIGURE 11 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY DRUG TYPE, 2022 & 2032 (USD MILLION) 51
FIGURE 12 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY DRUG TYPE, 2022 52
FIGURE 13 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, THERAPEUTIC AREA SEGMENT ATTRACTIVENESS, 2019-2032 (USD MILLION) 53
FIGURE 14 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY THERAPEUTIC AREA,
2022 & 2032 (USD MILLION) 54
FIGURE 15 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY THERAPEUTIC AREA, 2022 55
FIGURE 16 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, END USER SEGMENT ATTRACTIVENESS,
2019-2032 (USD MILLION) 58
FIGURE 17 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY END USER, 2022 & 2032 (USD MILLION) 59
FIGURE 18 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY END USER, 2022 60
FIGURE 19 NORTH AMERICA MARKET ANALYSIS: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, 2019-2032 (USD MILLION) 62
FIGURE 20 NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION) 63
FIGURE 21 NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY COUNTRY, 2022 64
FIGURE 22 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET PLAYERS: COMPETITIVE ANALSIS, 2022 70
FIGURE 23 COMPETITOR DASHBOARD: NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET 71
FIGURE 24 ALLUCENT: SWOT ANALYSIS 83
FIGURE 25 CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT 86
FIGURE 26 CHARLES RIVER LABORATORIES: SWOT ANALYSIS 87
FIGURE 27 EVOTEC AG: FINANCIAL OVERVIEW SNAPSHOT 89
FIGURE 28 EVOTEC AG: SWOT ANALYSIS 90
FIGURE 29 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: FINANCIAL OVERVIEW SNAPSHOT 92
FIGURE 30 LGC LIMITED: FINANCIAL OVERVIEW SNAPSHOT 95
FIGURE 31 EUROFINS SCIENTIFIC: FINANCIAL OVERVIEW SNAPSHOT 98
FIGURE 32 EUROFINS SCIENTIFIC: SWOT ANALYSIS 100
FIGURE 33 CREATIVE BIOLABS: SWOT ANALYSIS 103
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們